- Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B
-
Kwon YS, Choe YH, Chin HS
- KMID: 720597
- Yonsei Med J.
- 2001 Feb;42(1):134-136.
- doi: 10.3349/ymj.2001.42.1.134
Previous reported ocular complications of interferon alfa administration are extremely rare. These include oculomotor palsy, corneal allograft rejection, retinal hemorrhage and cotton wool patches. A 15-year-old boy... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Clinical Outcome Between Patients Continuing and Discontinuing Lamivudine Therapy in Acute Exacerbation After Viral breakthrough During Lamivudine Therapy in Chronic Hepatitis B
-
Eun JR
- KMID: 760645
- Korean J Hepatol.
- 2006 Jun;12(2):184-190.
BACKGROUNDS/AIMS: Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs. Moreover, the effect of continuous lamivudine therapy is unknown in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation of HBV DNA Level and Viral Breakthrough During Lamivudine Therapy for Chronic Hepatitis B
-
Park HS, Lee DH, Heo J, Kim GH, Kang DH, Song GA, Cho M
- KMID: 760644
- Korean J Hepatol.
- 2006 Jun;12(2):173-183.
BACKGROUND/AIMS: Lamivudine is an effective therapy in chronic hepatitis B patients, but the emergence of resistant hepatitis B virus (HBV) mutants is a major concern. This study was performed... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcome in Cases of Viral Breakthrough During Lamivudine Therapy in Chronic Hepatitis B Patients
-
Ahn SH, Chang YJ, Oh SN, Choi DW, Baek SJ, Jeong WS, Choi CW, Kim KO, Yim HJ, Jo NY, Bak JJ, Kim JS, Bak YT, Lee MS, Yeon JE, Byun KS, Lee CH
- KMID: 863114
- Korean J Hepatol.
- 2002 Dec;8(4):389-396.
BACKGROUND/AIMS: Long-term lamivudine therapy can induce the emergence of lamivudine resistant hepatitis B virus (HBV) mutants. Clinically emergence of the mutant is expressed by the reappearance of disappeared HBV... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 1085302
- Korean J Hepatol.
- 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course... -
- CITED
-
- Close
- SHARE
-
- Close
- The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
-
Yo IK, Kwon OS, Park JW, Lee JJ, Lee JH, Won IS, Na SY, Jang PK, Park PH, Choi DJ, Kim YS, Kim JH
- KMID: 2155289
- Clin Mol Hepatol.
- 2015 Mar;21(1):32-40.
- doi: 10.3350/cmh.2015.21.1.32
BACKGROUND/AIMS: Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient
-
Song JH, Kim SY, Shin JK, Hong SD, Rim KS, Park HN, Lee JH, Lee YB, Oh SH, Hwang SG
- KMID: 2373428
- Korean J Gastroenterol.
- 2016 Apr;67(4):216-219.
- doi: 10.4166/kjg.2016.67.4.216
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea
-
Kim BK, Kwon SY, Lee CH, Choe WH, Choi HM, Koo HW
- KMID: 1776812
- Korean J Hepatol.
- 2009 Mar;15(1):25-41.
- doi: 10.3350/kjhep.2009.15.1.25
BACKGROUND/AIMS: The purpose of this study was to evaluate the cost-effectiveness of 1 year and up to 5 years of antiviral treatment for chronic hepatitis B (CHB). METHODS: Two ten-health-state... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Reverse Transcriptase Gene Mutations in the Hepatitis B Virus at a University Hospital in Korea
-
Lee AJ, Lee CH, Jeon CH
- KMID: 1791925
- Ann Lab Med.
- 2014 May;34(3):230-234.
- doi: 10.3343/alm.2014.34.3.230
BACKGROUND: Most mutations in the reverse transcriptase (RT) gene of the hepatitis B virus (HBV) are related to resistance to antiviral agents. Cross-sectional studies on the mutations of this gene... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
-
Yang HW, Lee BS, Lee TH, Lee HY, Nam KW, Kang YW, Chae HB, Kim SH, Kim SB, Lee HI, Kim AN, Song IH, Lee SH, Kim HS
- KMID: 964717
- Korean J Intern Med.
- 2010 Dec;25(4):372-376.
- doi: 10.3904/kjim.2010.25.4.372
BACKGROUND/AIMS: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naive patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
-
Yim SY, Kim TH, Jun SS, Kim ES, Keum B, Seo YS, Yim HJ, Jeen YT, Chun HJ, Lee HS, Um SH, Kim CD, Won NH, Ryu HS
- KMID: 2412216
- Gut Liver.
- 2017 May;11(3):417-425.
- doi: 10.5009/gnl16148
BACKGROUND/AIMS: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection
-
Nam SW, Jung JJ, Bae SH, Choi JY, Yoon SK, Cho SH, Han JY, Han NI, Yang JM, Lee YS
- KMID: 1091865
- Korean J Intern Med.
- 2007 Jun;22(2):73-76.
- doi: 10.3904/kjim.2007.22.2.73
BACKGROUND: Spontaneous delayed clearance of hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection is a rare event. The aim of this study was to investigate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients
-
Lee HJ, Kim SY, Lee SM, Heo J, Kim HH, Chang CL, Lee EY, Son HC
- KMID: 2434483
- Ann Lab Med.
- 2012 Nov;32(6):420-425.
BACKGROUND: Treatment for chronic hepatitis B aims to suppress virus replication and virus sequestration in hepatocytes. Covalently closed circular (ccc) DNA is the template for transcription of viral genes and... -
- CITED
-
- Close
- SHARE
-
- Close
- The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease
-
Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, Jang JW, Kim CW, Bae SH, Choi JY, Yoon SK
- KMID: 1776815
- Korean J Hepatol.
- 2009 Mar;15(1):59-69.
- doi: 10.3350/kjhep.2009.15.1.59
BACKGROUNDS/AIMS: Serum retinol-binding protein 4 (RBP4) is known to be a specific transport protein for retinol, and has recently been reported to be associated with insulin resistance. Hyaluronic acid (HA)... -
- CITED
-
- Close
- SHARE
-
- Close
- HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B
-
Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS
- KMID: 1792811
- Korean J Gastroenterol.
- 2011 Jul;58(1):25-30.
- doi: 10.4166/kjg.2011.58.1.25
BACKGROUND/AIMS: Sustained HBV DNA reduction is necessary for biochemical remission, histological improvement, and prevention of complications. We analyzed the time taken from HBV DNA loss to viral breakthrough after antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
